Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series.
We describe a consecutive series of patients with hydroxychloroquine (HCQ) retinopathy. Their clinical features illustrate that with normal renal function there is no threshold for total dosage for HCQ toxicity; that color vision testing is important; that almost all patients complain of altered central vision as their first symptom; and that a normal optic fundus does not exclude the diagnosis. Finally, HCQ retinopathy may progress even when the agent is stopped.
Bienfang
D
D
Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, and Robert B. Brigham Multipurpose Arthritis and Musculoskeletal Disease Center, Boston, Massachusetts, USA.
Coblyn
J S
JS
Liang
M H
MH
Corzillius
M
M
D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D003118:Color Perception / Q000187:drug effects; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D008875:Middle Aged; D009885:Ophthalmology / Q000379:methods; D010808:Physical Examination; D012164:Retinal Diseases / Q000139:chemically induced* / Q000503:physiopathology; D014785:Vision, Ocular / Q000187:drug effects
D018501:Antirheumatic Agents; D006886:Hydroxychloroquine